# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA5250616 | B | Inhibition of C-terminal His6-tagged recombinant SARS-CoV-2 MPro transfected in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKM-E(Edans)-NH2 as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by FRET assay | Severe acute respiratory syndrome coronavirus 2 | 10 | ALA5247630 | assay format | Scientific Literature | |
2. | ALA5250622 | B | Binding affinity to C-terminal His6-tagged recombinant SARS-CoV-2 MPro transfected in Escherichia coli BL21 (DE3) assessed as dissociation constant by Cheng-Prusoff equation analysis | Severe acute respiratory syndrome coronavirus 2 | 10 | ALA5247630 | assay format | Scientific Literature | |
3. | ALA5250623 | P | Stability of compound in PBS buffer at pH 7 at 25 to 35 degreeC measured for 3 to 24 hrs by HPLC analysis | 1 | ALA5247630 | small-molecule physicochemical format | Scientific Literature | ||
4. | ALA5250624 | F | Antiviral activity against SARS-CoV-2 UC-1074 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by microscopic analysis | Severe acute respiratory syndrome coronavirus 2 | 5 | ALA5247630 | organism-based format | Scientific Literature | |
5. | ALA5250625 | F | Antiviral activity against SARS-CoV-2 RG2674 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by microscopic analysis | Severe acute respiratory syndrome coronavirus 2 | 4 | ALA5247630 | organism-based format | Scientific Literature | |
6. | ALA5250626 | F | Antiviral activity against SARS-CoV-2 NVDBB-2220 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by microscopic analysis | Severe acute respiratory syndrome coronavirus 2 | 4 | ALA5247630 | organism-based format | Scientific Literature | |
7. | ALA5250627 | T | Cytotoxicity against African green monkey Vero cells assessed as change in cell morphology by microscopic analysis | Chlorocebus sabaeus | 4 | ALA5247630 | cell-based format | Scientific Literature | |
8. | ALA5250628 | T | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by Coulter counter analysis | Chlorocebus sabaeus | 4 | ALA5247630 | cell-based format | Scientific Literature | |
9. | ALA5250629 | B | Binding affinity to C-terminal His6-tagged recombinant SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) assessed as thermal stability by measuring change in melting temperature by SYPRO orange dye based thermal shift assay | Severe acute respiratory syndrome coronavirus 2 | 3 | ALA5247630 | assay format | Scientific Literature | |
10. | ALA5250630 | B | Binding affinity to C-terminal His6-tagged recombinant SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by ITC assay | Severe acute respiratory syndrome coronavirus 2 | 3 | ALA5247630 | assay format | Scientific Literature | |
11. | ALA5250631 | B | Binding affinity to C-terminal His6-tagged recombinant SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) assessed as change in gibbs free energy by ITC assay | Severe acute respiratory syndrome coronavirus 2 | 3 | ALA5247630 | assay format | Scientific Literature | |
12. | ALA5250632 | B | Binding affinity to C-terminal His6-tagged recombinant SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) assessed as change in enthalpy by ITC assay | Severe acute respiratory syndrome coronavirus 2 | 3 | ALA5247630 | assay format | Scientific Literature | |
13. | ALA5250633 | B | Binding affinity to C-terminal His6-tagged recombinant SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) assessed as change in entropy by ITC assay | Severe acute respiratory syndrome coronavirus 2 | 3 | ALA5247630 | assay format | Scientific Literature | |
14. | ALA5250634 | F | Antiviral activity against HCMV AD-169 infected in HELF cells assessed as reduction in viral replication | Human betaherpesvirus 5 | 7 | ALA5247630 | organism-based format | Scientific Literature | |
15. | ALA5250635 | F | Antiviral activity against HCMV Davis infected in HELF cells assessed as reduction in viral replication | Human betaherpesvirus 5 | 7 | ALA5247630 | organism-based format | Scientific Literature | |
16. | ALA5250636 | F | Antiviral activity against thymidine kinase positive VZV OKA infected in HELF cells assessed as reduction in viral replication | Human alphaherpesvirus 3 | 7 | ALA5247630 | organism-based format | Scientific Literature | |
17. | ALA5250637 | F | Antiviral activity against thymidine kinase deficient VZV 07-1 infected in HELF cells assessed as reduction in viral replication | Human alphaherpesvirus 3 | 7 | ALA5247630 | organism-based format | Scientific Literature | |
18. | ALA5250638 | T | Cytotoxicity against HELF cells assessed as change in cell morphology | Homo sapiens | 7 | ALA5247630 | cell-based format | Scientific Literature |